These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 15078987

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter.
    Nettelbeck DM, Rivera AA, Balagué C, Alemany R, Curiel DT.
    Cancer Res; 2002 Aug 15; 62(16):4663-70. PubMed ID: 12183423
    [Abstract] [Full Text] [Related]

  • 3. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication.
    Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF.
    Hum Gene Ther; 2002 Sep 20; 13(14):1737-50. PubMed ID: 12396626
    [Abstract] [Full Text] [Related]

  • 4. Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro.
    Fontecedro AC, Lutschg V, Eichhoff O, Dummer R, Greber UF, Hemmi S.
    Virol J; 2010 Jul 29; 7():175. PubMed ID: 20670430
    [Abstract] [Full Text] [Related]

  • 5. Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells.
    Rivera AA, Davydova J, Schierer S, Wang M, Krasnykh V, Yamamoto M, Curiel DT, Nettelbeck DM.
    Gene Ther; 2004 Dec 29; 11(23):1694-702. PubMed ID: 15496964
    [Abstract] [Full Text] [Related]

  • 6. Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli.
    Hoffmann D, Wildner O.
    BMC Biotechnol; 2006 Aug 03; 6():36. PubMed ID: 16887042
    [Abstract] [Full Text] [Related]

  • 7. Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma.
    Liu Y, Ye T, Sun D, Maynard J, Deisseroth A.
    Hum Gene Ther; 2004 Jul 03; 15(7):637-47. PubMed ID: 15242524
    [Abstract] [Full Text] [Related]

  • 8. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
    Delgado-Enciso I, Cervantes-García D, Martínez-Dávila IA, Ortiz-López R, Alemany-Bonastre R, Silva-Platas CI, Lugo-Trampe A, Barrera-Saldaña HA, Galván-Salazar HR, Coronel-Tene CG, Sánchez-Santillán CF, Rojas-Martínez A.
    J Gene Med; 2007 Oct 03; 9(10):852-61. PubMed ID: 17729237
    [Abstract] [Full Text] [Related]

  • 9. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.
    Li X, Zhang YP, Kim HS, Bae KH, Stantz KM, Lee SJ, Jung C, Jiménez JA, Gardner TA, Jeng MH, Kao C.
    Cancer Res; 2005 Mar 01; 65(5):1941-51. PubMed ID: 15753394
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Engineering regulatory elements for conditionally-replicative adeno-viruses.
    Haviv YS, Curiel DT.
    Curr Gene Ther; 2003 Aug 01; 3(4):357-85. PubMed ID: 12871022
    [Abstract] [Full Text] [Related]

  • 14. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses.
    Hoffmann D, Meyer B, Wildner O.
    J Gene Med; 2007 Sep 01; 9(9):764-78. PubMed ID: 17640083
    [Abstract] [Full Text] [Related]

  • 15. The E4-6/7 protein functionally compensates for the loss of E1A expression in adenovirus infection.
    O'Connor RJ, Hearing P.
    J Virol; 2000 Jul 01; 74(13):5819-24. PubMed ID: 10846061
    [Abstract] [Full Text] [Related]

  • 16. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor.
    Takahashi M, Sato T, Sagawa T, Lu Y, Sato Y, Iyama S, Yamada Y, Fukaura J, Takahashi S, Miyanishi K, Yamashita T, Sasaki K, Kogawa K, Hamada H, Kato J, Niitsu Y.
    Mol Ther; 2002 May 01; 5(5 Pt 1):627-34. PubMed ID: 11991754
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Deletion analysis of Ad5 E1a transcriptional control region: impact on tumor-selective expression of E1a and E1b.
    Hedjran F, Shantanu K, Tony R.
    Cancer Gene Ther; 2011 Oct 01; 18(10):717-23. PubMed ID: 21818136
    [Abstract] [Full Text] [Related]

  • 19. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses.
    Bilsland AE, Merron A, Vassaux G, Keith WN.
    Cancer Res; 2007 Feb 01; 67(3):1299-307. PubMed ID: 17283167
    [Abstract] [Full Text] [Related]

  • 20. Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses.
    Jiang H, Alemany R, Gomez-Manzano C, Medrano DR, Lemoine MG, Olson MV, Alonso MM, Lee OH, Conrad CC, Yung WK, Fueyo J.
    Neoplasia; 2005 Aug 01; 7(8):723-9. PubMed ID: 16207474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.